2 Mar 2018 15:01
BUZZ-Verona Pharma: Soars on positive data from mid-stage study
** British drug developer's U.S.-listed shares up 16 pct at $16.44 in morning trade - second highest gainer amongst Nasdaq-listed companies ** data a
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
VRP.L Share News (VRP)
VRP Share
Price
VRP Share
News
VRP Share
Chat
VRP Share
Trades
VRP
Live RNS
VRP Share
Charts
VRP Broker
Ratings
VRP Directors
Deals
VRP Financial
Diary
VRP
Fundamentals
VRP Short
Positions
VRP
Media
VRP.L Information
- There is currently no data for VRP
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Small caps round-up: Transense Tech, Hightex, Verona Pharma
Tue, 28th Aug 2012 14:43
Transense Technologies, which provides sensor systems for the transportation and industrial markets, has reported that its trading division, Translogik, has received an initial order for its iTrack Tyre Temperature and Pressure Monitoring Systems for mining and off-the-road vehicles from its Indonesian distributor, AutoRFID Solutions. The system will be installed as part of a pilot scheme on three of the 168 vehicles at the ADARO mine in Indonesia, one of AutoRFID's clients. Graham Storey, Chief Executive Officer of Transense, said it is "very encouraging that our success in South Africa has triggered this order in what is a new territory for us".Hightex Group, a systems engineering company, has been selected, along with its Brazilian construction partner SEPA, to engineer and install the membrane structure of the roof of the Beira-Rio Stadium in Porto Alegre, a 2014 FIFA World Cup venue. The deal, which has a value in the region of €10m, marks the firm's second contract win in Brazil. The stadium is the fifth largest in Brazil, and will accommodate around 50,000 spectators. Work will begin immediately and is due to be completed in 2013. Verona Pharma, a drug discovery company, has been granted a new patent for its lead drug candidate, RPL554, in the US. The product is being developed for the treatment of patients with chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma. The company is currently carrying out clinical trials of the drug to further characterise its bronchodilator and anti-inflammatory effects. NR
More News
26 Sep 2016 09:39
Verona Pharma appoints sector veteran Morgan as CFO
(ShareCast News) - AIM listed drug development company Verona Pharma appointed sector veteran Piers John Morgan as chief financial officer on Monday, as the company prepares for clinical trials for its flagship drug. Chartered accountant Morgan has 25 years' financial experience and was previously c
Read more13 Sep 2016 12:04
Verona Pharma makes progress on new respiratory drug
(ShareCast News) - Verona Pharma, a UK based drug development company focused on first-in-class medicines to treat respiratory diseases, reported positive results on new drug "RPL554". The company's lead drug, RPL554, is a first-in-class drug currently in Phase 2 trials as a nebulized maintenance tr
Read more20 Jun 2016 15:02
20 Jun 2016 12:50
Verona Pharma secures funding for drug trial
(ShareCast News) - Shares in AIM-listed Verona Pharma rallied on Monday as the drug development company it had successfully secured funding commitments to raise gross proceeds of around £44.7m through a conditional placing that was significantly oversubscribed. Net proceeds from the placing with new
Read more3 Jun 2016 12:52
Verona Pharma's shares fall as higher R&D costs widen FY loss
(ShareCast News) - Shares in Verona Pharma sagged more than 8% as it turned in a wider full-year pre-tax loss of £8.9m, from a loss of £3.8m, thanks to higher research and development more than doubling. Chief executive Jan-Anders Karlsson said Verona had made substantial clinical progress with its
Read more15 Mar 2016 10:35
Verona Pharma excites with asthma trial results
(ShareCast News) - Verona Pharma has published further encouraging clinical results for its RPL554 drug to treat chronic obstructive pulmonary disorder (COPD). Tests among asthma patients found the inhaled drug, which has both bronchodilator and anti-inflammatory properties in the same active molecu
Read more21 Jan 2016 13:31